Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34628 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Georgios Tsakonas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, European Society for Medical Oncology, Hellenic Society of Medical Oncology.
Abstract (Originalsprache)
The presence of brain metastases (BM) is a negative prognostic factor for patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in patients with oncogene‐driven tumours, especially those with EGFR ‐mutated or ALK ‐rearranged tumours. Although targeted treatments demonstrate significant efficacy regarding BM, they only apply to a minority of NSCLC patients. On the other hand, systemic therapies for nononcogenic‐driven NSCLC with BM have shown limited clinical benefit. In recent years, immunotherapy alone or combined with chemotherapy has been adopted as a new standard of care in first‐line therapy. This approach seems to be beneficial to patients with BM in terms of efficacy and toxicity. Combined immune checkpoint inhibition as well as the combination of immunotherapy and radiation therapy show promising results with significant, but overall acceptable toxicity. A pragmatic approach of allowing enrolment of patients with untreated or symptomatic BM in randomised trials evaluating immune checkpoint inhibitors strategies, possibly coupled with central nervous system‐related endpoints may be needed to generate data to refine treatment for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden.
- Faculty of Medicine, University of Crete, Heraklion, Greece.
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
- Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, UK.
- Division of Cancer Sciences, University of Manchester, Manchester, UK.
ORCID-Profile: Georgios Tsakonas, Andreas Koulouris
Förderung
- AstraZeneca
- European Society for Medical Oncology
- Hellenic Society of Medical Oncology
- Merck
- Roche
Zitieren
APA
Tsakonas, G., Ekman, S., Koulouris, A., Adderley, H., Ackermann, C. J., & Califano, R. (2023). Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis. International Journal of Cancer. https://doi.org/10.1002/ijc.34628
Vancouver
Tsakonas G, Ekman S, Koulouris A, Adderley H, Ackermann CJ, Califano R. Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis. International Journal of Cancer. 2023. doi:10.1002/ijc.34628
BibTeX
@article{Tsakonas2023,
author = {Tsakonas, Georgios and Ekman, Simon and Koulouris, Andreas and Adderley, Helen and Ackermann, Christoph Jakob and Califano, Raffaele},
title = {Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34628}
}
EUVIMED